Beth A. Overmoyer

Internal Medicine
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.

Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer.

Journal: Cell reports. Medicine
Published: October 30, 2025

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies.

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapies.

Journal: bioRxiv : the preprint server for biology
Published: September 05, 2025

The Clinicopathologic Features of Inflammatory Breast Carcinoma (IBC) With Lobular Features.

The Clinicopathologic Features of Inflammatory Breast Carcinoma (IBC) With Lobular Features.

Journal: The American journal of surgical pathology
Published: July 03, 2025

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.

Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.

Journal: Breast cancer research : BCR
Published: January 30, 2025

Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score.

Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score.

Journal: Journal of the National Cancer Institute
Published: December 06, 2024

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).

Journal: Nature communications
Published: October 18, 2024

Clinicogenomic Characterization of Inflammatory Breast Cancer.

Clinicogenomic Characterization of Inflammatory Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 02, 2024

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.

Journal: ESMO open
Published: June 13, 2024

Clinicogenomic characterization of inflammatory breast cancer.

Clinicogenomic characterization of inflammatory breast cancer.

Journal: bioRxiv : the preprint server for biology
Published: May 20, 2024

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.

Journal: Neuro-oncology
Published: December 09, 2023

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.

Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.

Journal: The Lancet. Oncology
Published: October 13, 2023

TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.

TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.

Journal: Breast cancer research : BCR
Published: September 14, 2023
Showing 1-12 of 76

Last Updated: 09/26/2026